Volume 83, Issue 9 (December 2025)
Tehran Univ Med J. 2025, 83(9): 647-655 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimi H, Shirinsahraee N, Oroojan A A. Effects of trijardy XR on BMI, lipid profile, and vitamin D levels in type 2 diabetic patients resistant to metformin/sitagliptin therapy. Tehran Univ Med J. 2025; 83 (9) :647-655
URL: http://tumj.tums.ac.ir/article-1-13861-en.html
URL: http://tumj.tums.ac.ir/article-1-13861-en.html
1- Department of Internal Medicine, Student Research Committee, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran.
2- Department of Physiology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran. ,aliakbar_oroojan@yahoo.com
2- Department of Physiology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran. ,
Abstract: (80 Views)
Background: Trijardy XR, a combination of empagliflozin, linagliptin, and metformin, has shown promising effects on various disease-modifying variables in type 2 diabetes. This study aimed to investigate the effect of Trijardy XR on fasting blood sugar, glycosylated hemoglobin, body mass index, lipid profile, and vitamin D levels in type 2 diabetic patients refractory to metformin and sitagliptin treatment.
Methods: The present quasi-experimental study included 28 type 2 diabetic patients over 18 years of age with body mass index between 25-45, glycosylated hemoglobin between 7.10-5.00, fasting blood sugar between 126-250 mg/dL, and glomerular filtration rate greater than 30 who were refractory to metformin and sitagliptin in the previous 12 weeks. Patients were treated with a fixed-dose combination of empagliflozin (12.5 mg), linagliptin (2.5 mg), and metformin (1000 mg) for 3 months. At the end of the study, fasting blood sugar, glycosylated hemoglobin, lipid profile, vitamin D levels, and body mass index were reassessed through blood tests.
Results: Fasting blood sugar (P<0.05), glycosylated hemoglobin (P<0.001), and body mass index (P<0.001) were significantly reduced in patients treated with Trijardy XR compared with the previous metformin and sitagliptin regimen. There were no significant differences in serum triglyceride, Low-density lipoprotein, High-density lipoprotein, Very Low-Density Lipoprotein, or vitamin D levels before and after treatment with Trijardy XR. However, the Low-density lipoprotein to High-density lipoprotein ratio was significantly reduced in patients receiving Trijardy XR (P<0.05).
Conclusion: Treatment with Trijardy XR improved fasting blood sugar, glycosylated, and body mass index, as well as reduced Low-density lipoprotein to High-density lipoprotein ratio, a potential risk factor for cardiovascular disease, in a shorter period of time compared to treatment with metformin and sitagliptin in patients with type 2 diabetes.
Methods: The present quasi-experimental study included 28 type 2 diabetic patients over 18 years of age with body mass index between 25-45, glycosylated hemoglobin between 7.10-5.00, fasting blood sugar between 126-250 mg/dL, and glomerular filtration rate greater than 30 who were refractory to metformin and sitagliptin in the previous 12 weeks. Patients were treated with a fixed-dose combination of empagliflozin (12.5 mg), linagliptin (2.5 mg), and metformin (1000 mg) for 3 months. At the end of the study, fasting blood sugar, glycosylated hemoglobin, lipid profile, vitamin D levels, and body mass index were reassessed through blood tests.
Results: Fasting blood sugar (P<0.05), glycosylated hemoglobin (P<0.001), and body mass index (P<0.001) were significantly reduced in patients treated with Trijardy XR compared with the previous metformin and sitagliptin regimen. There were no significant differences in serum triglyceride, Low-density lipoprotein, High-density lipoprotein, Very Low-Density Lipoprotein, or vitamin D levels before and after treatment with Trijardy XR. However, the Low-density lipoprotein to High-density lipoprotein ratio was significantly reduced in patients receiving Trijardy XR (P<0.05).
Conclusion: Treatment with Trijardy XR improved fasting blood sugar, glycosylated, and body mass index, as well as reduced Low-density lipoprotein to High-density lipoprotein ratio, a potential risk factor for cardiovascular disease, in a shorter period of time compared to treatment with metformin and sitagliptin in patients with type 2 diabetes.
Type of Study: Original Article |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
